NoticeThis is an independent non-profit initiative. We are not affiliated with the European Medicines Agency (EMA) or the official CTIS system. For the official EU Clinical Trials Information System, visit:
EMA Registry →
Anemia due to MDS with del5q with IPSS-R very low, low, or intermediate risk MDS and abone marrow blast count of < 5% , Refractory or intolerant to, or ineligible for, prior ESA treatment and for prior lenalidomide treatment and who require RBC transfusions.
1 total trials1 recruiting
Filter these 1 trials by phase, country, sponsor and more.